N@N

VIROPHARMA INC (NASDAQ:VPHM), Up By 9.29% ($1.49) From $16.040 After BUYINS.NET Report Predicted Strength After Earnings

^{Published on 2011-02-26 09:01:34 - WOPRAI}
 

February 25, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, February 23rd 2011 stating that VIROPHARMA INC (NASDAQ:VPHM) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=vphm&id=148924

At the time this story was written, VIROPHARMA INC (NASDAQ:VPHM) is Up By 9.29% ($1.49) From $16.040 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

VIROPHARMA INC (NASDAQ:VPHM) - ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. The companys product line includes Cinryze for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema; and Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Its products in development include C1 esterase inhibitor to identify further therapeutic uses and potential additional indications and other modes of administration for the treatment of HAE and other C1 mediated diseases; a non-toxigenic strain of C. difficile for the treatment and prevention of CDI.; and Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus infections related to transplant. The company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. VIROPHARMA INC (NASDAQ:VPHM) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net